|
|
 |
International China Pharma R&D Summit 2012
（中國醫藥品研究開發高峰會議）
2012年4月23-26日 | 上海, 中國
請勿錯過第7屆China Pharmaceutical R&D Summit
是獲得在中國製藥公司和生物技術企業活躍的經營主管大力支持的生命科學業界重要學會，且是能吸收新知、建構人際關係、以及合作關係邁向新階段的寶貴機會。
因中國製藥公司和生物技術企業許多主要主管參加而廣被人知的此學會，往年不僅是亞洲、來自世界各國的企業和團體超過400人高階主管齊聚一堂，針對醫藥品研究開發的創新手法和新開發模式等展開熱烈的討論。聆聽專家的報告，見到可作為合作對象的企業代表，且是亞洲能獲得有助於研究開發策略再調整之新見識的唯一學會，就是China Pharmaceutical R&D Summit。
有多場深受矚目的演講
|
由全球主要的製藥公司主管進行演講 |
|
|
Joe McCracken, Global Head of Business
Development and Licensing, Roche, USA
Helmut Haning, Senior Vice President, Head of Global Innovati on Sourcing, Bayer Schering Pharma, Germany
Ling Chen, Vice President of R&D China Operations, GlaxoSmithKline |
Roxanne de la Riva, Head of Genentech Research and Early Development (gRED) Procurement, Genentech, USA
Frank Shen, Vice President Global Data
Management and Stati sti cs, Global Pharmaceutical R&D, Abbott, USA
Mary Haak-Frendscho, President and Chief Scientific Officer, Takeda San Francisco, USA |
|
由學界領袖進行演講 |
|
|
Susan Windham-Bannister, President,
Massachusetts Life Science Center, USA
Ralf Altmeyer, Director General, Institut Pasteur, China
Hongbin Sun, Director, Center for Drug Discovery, China Pharmaceutical University |
Kewei Wang, Professor and Chair, Department of Molecular and Cellular Pharmacology, Peking University School of Pharmaceutical Sciences, China
Yuqiang Wang, Professor and Dean, Jinan
University College of Pharmacy, China |
|
而且亦預定有亞洲地區製藥業界有關人員的演講 |
|
|
Herng-Der Chern, Distinguished Research Fellow, Center for Drug Evaluation, Taiwan
Zhenping Zhu, President & Chief Executive Officer, Kadmon China
John Oyler, Chief Executive Officer and Founder, Beigene, China
Vijay Karwal, Managing Director, Royal Bank of Scotland, Hong Kong
Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals, Singapore |
Satheeshkumar Sriharan, Chief Representative / Country Head-China, Dr Reddy’s Laboratories, China
Li Chen, President & Chief Executive Officer, Hua Medicine, China
Jonathan Wang, Partner, Legend Capital, China
Youling Wu, Chief Executive Officer, ZheJiang Teruisi, China |
And more...
|
| - |
迎接第7年，規模和內容更加進化的China Pharma R&D Summit與2個學會同時舉辦
 and  |
| - |
計畫的構成創新，可期待展開熱烈的討論 |
| - |
能聆聽製藥業界和學界新成員的演講者發表嶄新的見解 |
| - |
展示亞洲製藥業界引人注目的創新產品 |
| - |
了解構成亞洲主要市場的各國法規最新動向 |
| - |
有力的投資公司和大製藥公司的主管，針對影響深遠的投資議案和資金籌措議案展開議論 |
| - |
聚焦於醫藥品的研究開發，是亞洲歷史最悠久的國際性學會，能吸收新知，以及建構重要的人際關係 |
|
|
|
|
|
|
|
會前研討會 小型會議A • 2012年4月23日
U.S. Market Entry:
A Regulatory, Legal, and Medical
Communication Perspective |
會後研討會 小型會議 B • 2012年4月26日
Turning Strategies into Tactical Plans to Optimize Market Entry – Balancing Commercial, Regulatory and Investments to Deliver Successful Business Models |
|
|
|
|
|
|
| |
|
 |
AGENDA AT A GLANCE |
|
| |
|
AM |
LUNCH |
PM |
星期一
4月23日 |
Pre-Conference Workshops:
US Market Entry: A Regulatory, Legal, and Medical Communication Perspective (Full Day)
Expression Systems for Antibody and Vaccine Biomanufacturing (Full Day) |
LUNCH,
AM & PM BREAKS |
US Market Entry: A Regulatory, Legal, and Medical Communication Perspective
Expression Systems for Antibody and Vaccine Biomanufacturing
Meet the Speakers Reception (by Invitation only) |
(火)
4月24日 |
China Pharma R&D, Vaccines & Biosimilars
JOINT PLENARY SESSION
Global and Regional Keynote Presentations
On Pharma R&D |
EXHIBITION & POSTER SESSION
DISCUSSION DEN
CRO Clinic / Onsite “Lab’ & Demonstrations
China Technology & Services Pavilion |
China Pharmaceutical R&D Summit
• Regulatory Snapshots
• R&D Leaders Panel
• Investment & Funding
• ‘Pharma Idol’: Innovation
Showcase
• CXO Panel Discussion
• Funding for Innovation |
Discussion Den:
In depth roundtable discussions on Regulatory and
Collaborations in Key Asian Countries
NETWORKING RECEPTION
EVENING DINNER (Optional) |
Vaccines China
• Market Trends & Outlook
• Vaccines Quality Control &
Compliance
• Novel Development of Vaccines
• Regulatory Snapshots
• Visionary Panel Discussion |
Biosimilars Asia
• Market Entry & Opportunities
• Commercial Viability
• Regulatory Snapshots
• Visionary Panel Discussion |
|
星期三
4月25日 |
China Pharmaceutical R&D Summit
• Drug Development & Partnering Strategies
• Emerging Business Models< in R&D
• Discovery & Early Stage Devt
• Role of Academia in Drug
Discovery & Development |
Vaccines China
• Novel Vaccine Candidates for Tropical Diseases
• Research and Clinical Updates for EV71 vaccines |
Biosimilars Asia
• External Collaborations & Commercial Value
• Breaking into Protectionist Markets
• Intellectual Property Legal Debate |
|
China Pharmaceutical R&D
Summit
• ‘Pharma Idol’: Innovation Showcase and Awarding
• Clinical Development & Partnerships in Asia
• Future Opportunities in Biosimilars & Biobetters
• Closing Visionary Panel Discussion |
Vaccines China
• Innovations & Technological Advancements
• Future Opportunities for Sustainable Return on Investment |
Biosimilars Asia
• Mad about mAbs
• Developing Biosimilars & Biobetters
• Winning Buy-in
• Closing Panel Debate |
|
星期四
4月26日 |
Post-Conference Workshops:
Next Generation of Vaccine Facilities
with Focus on Design & Containment
Turning Strategies into Tactical
Plans to Optimize Market Entry –
Balancing Commercial, Regulatory
and Investments to Deliver Successful
Business Models |
|
|
|
.jpg)
